Lonsurf® Treatment for Colorectal Cancer - CancerConnect
La trifluridine plus le tipiracil et le bévacizumab est une nouvelle norme de soins pour le cancer colorectal métastatique réfractaire
Continued Avastin Extends Survival After 1st Progression in Colorectal Cancer - CancerConnect
Benefits & Risks of Treatment | Metastatic Colorectal Cancer (mCRC)| Avastin® (bevacizumab)
Adding Avastin to Lonsurf Improved Outcomes in Pretreated Colorectal Cancer
La trifluridine plus le tipiracil et le bévacizumab est une nouvelle norme de soins pour le cancer colorectal métastatique réfractaire
Avastin® (bevacizumab) Dosing | MCRC Treatment
How to Take LONSURF® (trifluridine and tipiracil) tablets | Helpful Dosage Reminders
Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
Precision treatment in colorectal cancer: Now and the future - Yau - 2019 - JGH Open - Wiley Online Library
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Avastin and Lonsurf for Advanced Colorectal Cancer - NCI
Nanotechnologies for the treatment of colon cancer: From old drugs to new hope - ScienceDirect
Trifluridine/tipiracil plus bevacizumab prolongs survival in refractory colorectal cancer
NEJM on X: "This editorial describes the science behind a clinical trial performed by Prager and colleagues: a test of trifluridine–tipiracil and bevacizumab to treat patients with refractory metastatic colorectal cancer. https://t.co/Y1QlV28qsr" /
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF. LONSURF (trifluridine and tipiracil) tablets, for oral use Initial U.S. Approval:
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer | NEJM
Current Oncology | Free Full-Text | A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer | NEJM
Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
NCCN® Guidelines for Metastatic Colon Cancer Treatment
